Home > SCENESSE® > Drug Product
    Drug Product PDF Print E-mail

     

    The 16mg afamelanotide implant
    The 16mg Scenesse implant
    Clinuvel has developed the concept of medicinal photoprotection and has refined the technology over the last five years to optimize the photoprotective effect of Scenesse (Afamelanotide). The company has formulated a 16mg controlled-release subcutaneous implant for the delivery of scenesse.

    Roughly the size of a grain of rice, the implant is injected underneath the skin. Skin pigmentation is activated immediately and the photoprotective effect lasts up to two months.

    Scenesse has a relatively short half life (less than 50 minutes) and trials to date have raised no serious safety concerns; thus far the drug is well tolerated by patients. The implant drug product has been chosen for its ease of use in dermatology.

    Scenesse is the first melanocortin to be developed into a pharmaceutical product. To date, Clinuvel has spent over A$80 million developing the Scenesse implant drug product as a therapeutic photoprotective drug for patients who are most at risk from UV and sun exposure.